

SARS-CoV-2 Nucleic Acid Amplification Test, Combined SARS-CoV-2 + Flu A/B Nucleic Acid Amplification Test, Point of Care, Emergency Centers (Excluding Canton and Lenox)

Effective Date: October 26, 2021

Laboratory Bulletin

Beaumont Laboratory will be replacing the hospital-based emergency department Point of Care SARS-CoV-2 antigen tests with SARS-CoV-2 nucleic acid amplification (RT-PCR) tests. The new Point of Care tests produce results in 20 minutes and use RT-PCR technology that is considered the gold-standard for diagnosing SARS-CoV-2 infection. Test results obtained with the Point of Care Roche cobas Liat SARS-CoV-2 and SARS-CoV-2/Flu A+B combo nucleic acid amplification (RT-PCR) test are comparable to laboratory-based RT-PCR tests and **do not need to be confirmed**, so long as an “invalid” result is not produced. This is supported by internal validation data and published literature.

Orders can be placed in Epic oneChart and all order-entry questions must be answered. Test selection should be based on currently circulating respiratory viruses. When influenza is circulating (typically December-March), the SARS-CoV-2 + Flu A/B combo test can aid in the diagnosis of COVID-19 and/or Influenza A/B infection. Outside of flu season, only the SARS-CoV-2 test may be needed. Note: Testing availability is pending vendor allocation/reagent availability. Specimens that may require additional testing can be stored in the main laboratory by ordering a “RAINBOW EXTRA OTHER TUBE” (LAB8490) test in Epic and placing a printed label on the specimen prior to sending to the main laboratory.

Test Information:

SARS-CoV-2 Only

Name: SARS-COV-2 (COVID-19) by Nucleic Acid Amplification, POC
Order Code: LAB8528
CPT Code: 87635
Specimen: Nasopharyngeal swab (1.5 mL MedSchenker Media)

SARS-CoV-2 + Flu A/B Combo

Name: SARS-COV-2 (COVID-19) and Influenza AB by Nucleic Acid Amplification, POC
Order Code: LAB8527
CPT Code: 87636
Specimen: Nasopharyngeal swab (1.5 mL MedSchenker Media)

Date submitted: October 19, 2021
Submitted by: Steven M. Truscott, PhD, DABCC, Technical Director, Special Chemistry, STAT Lab, Point of Care Testing
Daniel Ortiz, PhD, D(ABMM), System Director, Microbiology and Molecular Pathology